Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland.

Bainbridge J, Mealing S, Graham C, Jenal M, von Dombrowski N, Dymond A

Open source

DOI
10.1007/s40258-026-01063-1
Published
2026 Aug 12
Container
Applied health economics and health policy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40258-026-01063-1,
  title = {Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland.},
  author = {Bainbridge J and Mealing S and Graham C and Jenal M and von Dombrowski N and Dymond A},
  year = {2026},
  journal = {Applied health economics and health policy},
  doi = {10.1007/s40258-026-01063-1},
  url = {https://doi.org/10.1007/s40258-026-01063-1}
}

RIS

TY  - JOUR
TI  - Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland.
AU  - Bainbridge J
AU  - Mealing S
AU  - Graham C
AU  - Jenal M
AU  - von Dombrowski N
AU  - Dymond A
PY  - 2026
JO  - Applied health economics and health policy
DO  - 10.1007/s40258-026-01063-1
UR  - https://doi.org/10.1007/s40258-026-01063-1
ER  - 

APA

J, B., S, M., C, G., M, J., N, V. D., & A, D. (2026). Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland.. Applied health economics and health policy. https://doi.org/10.1007/s40258-026-01063-1

Source records